In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

**Active Ingredient:** Baloxavir marboxil  
**Dosage Form; Route:** Tablet; Oral  
**Recommended Studies:** Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 80 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females  
   **Additional comments:** Ensure an adequate washout period between treatments in the crossover study due to the long elimination half-life of baloxavir. Alternatively, a parallel study design may be considered (refer to FDA approved reference product labeling with regard to the pharmacokinetic differences between Asians and non-Asians).

2. **Type of study:** Fed  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 80 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females  
   **Additional comments:** See comments above.

**Analyte to measure:** Baloxavir in plasma  
**Bioequivalence based on (90% CI):** Baloxavir  
**Waiver request of in vivo testing:** 40 mg strength based on (i) acceptable bioequivalence studies on the 80 mg strength, (ii) acceptable in vitro dissolution testing of both strengths, and (iii) proportional similarity of the formulations between both strengths
Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution. Conduct comparative dissolution testing on 12 dosage units for each of both strengths of the test and reference products. Specifications will be determined upon evaluation of the abbreviated new drug application.

Revision History: Recommended September 2019; Revised May 2023

Unique Agency Identifier: PSG_210854